A clinical-stage biotechnology company, Climb Bio develops monoclonal antibody therapies targeting immune-mediated diseases. The company's lead candidate, budoprutug, is an anti-CD19 antibody in clinical development for B-cell mediated conditions including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. Additionally, the company is developing CLYM116, a preclinical anti-APRIL monoclonal antibody for immunoglobulin A nephropathy.
The company operates as a clinical-stage entity without disclosed revenue streams, relying on capital financing to fund development activities. Climb Bio was incorporated in Delaware in 2018 and operates from its headquarters in Wellesley Hills, Massachusetts. The organization maintains a lean operational structure with 17 full-time employees. The company changed its name from Eliem Therapeutics to Climb Bio in October 2024 and is listed on the Nasdaq exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.53 | $-1.53 | -17.7% | |
| 2023 | $-1.30 | $-1.30 | +24.4% | |
| 2022 | $-1.72 | $-1.72 | — | |
| 2021 | — | — | — |